Navigation Links
Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
Date:6/27/2012

SAN DIEGO, June 27, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the appointment of Carolyn Beaver to Vice President and Chief Accounting Officer. 

"Carolyn's strong background and financial acumen make her an extremely valuable complement to the Sequenom management team," said Paul Maier, Sequenom's Chief Financial Officer. "We look forward to her contributions in continuing to pursue functional excellence in finance and accounting within our growing organization."

Ms. Beaver was previously employed with Beckman Coulter, Inc., a global biomedical testing manufacturer, and served in various roles, including Corporate Vice President, Controller and Chief Accounting Officer since August 2005.  Since its acquisition by Danaher Corp. in June 2011, Ms. Beaver continued to serve at Beckman Coulter, Inc. as the Corporate Vice President, Controller.  From 1987 until 2002, Ms. Beaver was a partner with KPMG LLP.  Ms. Beaver also currently serves as a director of Commerce National Bank, a position she has held since 2005.  Ms. Beaver holds a B.S. in Accounting from California State Polytechnic University, Pomona.

In connection with her appointment, Ms. Beaver received a nonqualified stock option grant for 100,000 shares of common stock under our New Hire Equity Incentive Plan.  The option has an exercise price of $4.14, which was equal to the closing price of Sequenom's common stock on June 26, 2012, the effective date of her employment. This option will vest and become exercisable by Ms. Beaver over four years, with 25% vesting on June 26, 2013 and ratably monthly thereafter, subject to her continued service through the applicable vesting dates. The option will expire after ten years. This option is granted as an inducement grant pursuant to Section 5635(c)(4) of the Nasdaq Marketplace Rules.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Ms. Beaver's expected contributions to Sequenom's growing organization, and  Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation, including patent litigation, and other risks detailed from time to time in Sequenom, Inc.'s most recent Annual Report on Securities and Exchange Commission Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom Announces Participation at the Jefferies Global Healthcare Conference
2. Study In Prenatal Diagnosis Finds Sequenom CMMs MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets
3. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
4. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
5. Sequenom Named to NASDAQ Global Select Market
6. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
7. Sequenom to Host Analyst Day on Monday, November 14, 2011
8. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
9. Oil 4 Less LLC, the Home of Codatron TM Announces New Management Headquarters
10. United Therapeutics Announces Additional $100 Million Share Repurchase Program
11. Qualyst Transporter Solutions, LLC Announces Launch of New FDA Services Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):